Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;11(18):2443-56.
doi: 10.2217/nnm-2016-0194. Epub 2016 Aug 16.

Targeted nanoparticles for colorectal cancer

Bruno A Cisterna  1 , Nazila Kamaly  2   3 , Won Il Choi  2   4 , Ali Tavakkoli  5 , Omid C Farokhzad  2   6 , Cristian Vilos  1   2   7
Affiliations
Review

Targeted nanoparticles for colorectal cancer

Bruno A Cisterna et al. Nanomedicine (Lond). 2016 Sep.

Abstract

Colorectal cancer (CRC) is highly prevalent worldwide, and despite notable progress in treatment still leads to significant morbidity and mortality. The use of nanoparticles as a drug delivery system has become one of the most promising strategies for cancer therapy. Targeted nanoparticles could take advantage of differentially expressed molecules on the surface of tumor cells, providing effective release of cytotoxic drugs. Several efforts have recently reported the use of diverse molecules as ligands on the surface of nanoparticles to interact with the tumor cells, enabling the effective delivery of antitumor agents. Here, we present recent advances in targeted nanoparticles against CRC and discuss the promising use of ligands and cellular targets in potential strategies for the treatment of CRCs.

Keywords: cancer therapy; colorectal cancer (CRC); controlled release; drug delivery; targeted nanoparticles.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

OC Farokhzad acknowledges NIH support from grants HL127464, CA151884 and EB015419; and by the David Koch-Prostate Cancer Foundation Award in Nanotherapeutics. C Vilos acknowledges support from FONDECYT regular grant no. 1161438, UNAB Regular Grant DI-695-15/R, MECESUP PMI-UAB1301, and the Basal Program for Centers of Excellence, grant FB0807 CEDENNA, CONICYT. The authors declare the following competing financial interest(s): OC Farokhzad has financial interests in BIND Therapeutics, Selecta Biosciences, Tarveda Therapeutics and Placon Therapeutics, which are developing nanoparticle technologies for medical applications. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Stages of colorectal cancer according to the American Joint Committee on Cancer.
Stage 0; tumor confined to mucosa (carcinoma in situ). Stage I: tumor invades submucosa and muscularis propria. Stage II: tumor invades through the muscularis propria into pericolorectal tissues (IIA), then penetrates to the surface of the visceral peritoneum (IIB), then directly invades or is adherent to other organs or structures (IIC). Stage III: tumor invades muscularis propria with metastases in 1–3 regional lymph nodes or nearby tissue, or invades submucosa with metastases in 4–6 regional lymph nodes (IIIA). Then tumor penetrates to the surface of the visceral peritoneum with metastases in 1–3 regional lymph nodes or nearby tissue, or invades through the muscularis propria into pericolorectal tissues with metastases in 4–6 regional lymph nodes, or invades muscularis propria with metastases in 7 or more regional lymph nodes (IIIB). Then tumor penetrates to the surface of the visceral peritoneum with metastases in 4–6 regional lymph nodes, or invades through the muscularis propria into pericolorectal tissues with metastases in 7 or more regional lymph nodes, or directly invades or is adherent to other organs or structures with metastases in one or more regional lymph nodes (IIIC). Stage IV: metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional node).
<b>Figure 2.</b>
Figure 2.. Targeted nanoparticle strategy for colorectal cancer.
The most common CRC biomarkers overexpressed in the cellular membrane and the typical molecules/ligands used on the surface of nanoparticles in targeting strategies: FR-α, EGFR, TAG-72. CEA: Carcinoembryonic antigen; CRC: Colorectal cancer; EGFR: EGF receptor; FR-α: Folate receptor-α; TAG-72: Tumor-associated glycoprotein.
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015;65(2):87–108. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015;65(1):5–29. - PubMed
    1. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual. Springer; NY, USA: 2010. Colon and rectum; pp. 143–164.
    1. Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumours. International Union Against Cancer, Wiley-Blackwell Chichester; Sussex, UK; NJ, USA: 2010. Colon and rectum; p. 309.
    1. Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu. Rev. Med. 2015;66:83–95. - PubMed

MeSH terms

Substances